A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer Meeting Abstract
| Authors: | Chung, C. H.; Colevas, A. D.; Adkins, D.; Gibson, M. K.; Rodriguez, C. P.; Sukari, A.; Bauman, J. E.; Wirth, L. J.; Johnson, F. M.; Saba, N. F.; Burtness, B.; Dunn, L.; Seiwert, T. Y.; Worden, F. P.; Muzaffar, J.; Margossian, S.; Moniz, R.; Quayle, S. N.; Levisetti, M.; Pai, S. I. |
| Abstract Title: | A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301746 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.6045 |
| Notes: | Meeting Abstract: 6045 -- This meeting was also held virtually -- Source: Wos |
